10-Q · 2026-11-09
Trevi Therapeutics, Inc. releases Q3 results, showing advancements in clinical trials and ongoing commitment to pharmaceutical innovation.
| Name | Trevi Therapeutics, Inc. |
|---|---|
| CIK | 0001563880 |
| Tickers | TRVI |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 450834299 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 203-304-2499 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Trevi Therapeutics, Inc. releases Q3 results, showing advancements in clinical trials and ongoing commitment to pharmaceutical innovation.
Trevi Therapeutics announces its financial results for Q3 2026, highlighting progress in developing new therapies in the pharmaceutical sector.
540 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001231919-26-001580 | 005-91005 | 261561358 | 34 | 28586 | |||
| 2026-11-09 | 10-Q | 10-Q | 0001193125-26-453674 | 001-38886 | 261536384 | 34 | 8643067 | 1 | 1 | |
| 2026-11-09 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-453670 | 001-38886 | 261536349 | 34 | 372065 | 1 | 1 |
| 2026-10-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-003855 | 005-91005 | 261491705 | 34 | 11135 | |||
| 2026-09-17 | 4 | 4 | 0001193125-26-394456 | 17103 | ||||||
| 2026-09-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-009512 | 001-38886 | 261381335 | 33 | 4802 | |||
| 2026-08-06 | S-8 | S-8 | 0001193125-26-338071 | 333-298056 | 261249313 | 33 | 309663 | 1 | 1 | |
| 2026-08-06 | 10-Q | 10-Q | 0001193125-26-338023 | 001-38886 | 261249173 | 34 | 8512727 | 1 | 1 | |
| 2026-08-06 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-337974 | 001-38886 | 261248991 | 34 | 372567 | 1 | 1 |
| 2026-08-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002184 | 005-91005 | 261247284 | 34 | 11716 | |||
| 2026-06-04 | 4 | 4 | 0001193125-26-257488 | 5501 | ||||||
| 2026-06-04 | 8-K | 8-K | 5.03,5.07,9.01 | 0001193125-26-257365 | 001-38886 | 261064887 | 34 | 227203 | 1 | 1 |
| 2026-06-04 | 4 | 4 | 0001193125-26-257370 | 5550 | ||||||
| 2026-06-04 | 4 | 4 | 0001193125-26-257373 | 5573 | ||||||
| 2026-06-04 | 4 | 4 | 0001193125-26-257371 | 5529 | ||||||
| 2026-06-04 | 4 | 4 | 0001193125-26-257366 | 5598 | ||||||
| 2026-05-07 | SCHEDULE 13D/A | xslSCHEDULE_13D_X02/primary_doc.xml | 0001072613-26-000382 | 005-91005 | 26955316 | 34 | 104104 | |||
| 2026-05-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-001314 | 005-91005 | 26946978 | 34 | 11277 | |||
| 2026-05-05 | 10-Q | 10-Q | 0001193125-26-206390 | 001-38886 | 26943135 | 34 | 7376721 | 1 | 1 | |
| 2026-05-05 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-206382 | 001-38886 | 26943074 | 34 | 339355 | 1 | 1 |
| 2026-04-21 | DEF 14A | DEF 14A | 0001193125-26-166695 | 001-38886 | 26879238 | 34 | 5751636 | 1 | 1 | |
| 2026-04-21 | DEFA14A | DEFA14A | 0001193125-26-166693 | 001-38886 | 26879233 | 34 | 2208822 | 1 | 1 | |
| 2026-04-21 | ARS | ARS | 0001193125-26-166694 | 001-38886 | 26879229 | 34 | 1765169 | |||
| 2026-04-17 | 424B5 | 424B5 | 0001193125-26-161582 | 333-291517 | 26871816 | 33 | 702074 | 1 | 1 | |
| 2026-04-17 | 8-K | 8-K | 1.01,2.02,8.01,9.01 | 0001193125-26-160355 | 001-38886 | 26869468 | 34 | 479218 | 1 | 1 |
| 2026-04-16 | 424B5 | 424B5 | 0001193125-26-159041 | 333-291517 | 26867788 | 33 | 558794 | |||
| 2026-04-10 | PRE 14A | PRE 14A | 0001193125-26-151354 | 001-38886 | 26855343 | 34 | 5731941 | 1 | 1 | |
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-002401 | 005-91005 | 26804763 | 34 | 7169 | |||
| 2026-03-17 | 10-K | 10-K | 0001193125-26-110783 | 001-38886 | 26761913 | 34 | 15425628 | 1 | 1 | |
| 2026-03-17 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-110767 | 001-38886 | 26761868 | 34 | 372806 | 1 | 1 |
| 2026-03-09 | 8-K | 8-K | 8.01 | 0001193125-26-098676 | 001-38886 | 26735569 | 34 | 164711 | 1 | 1 |
| 2026-02-20 | 4 | 4 | 0001193125-26-061399 | 5350 | ||||||
| 2026-02-20 | 4 | 4 | 0001193125-26-061396 | 5392 | ||||||
| 2026-02-20 | 4 | 4 | 0001193125-26-061394 | 5344 | ||||||
| 2026-02-20 | 4 | 4 | 0001193125-26-061391 | 5334 | ||||||
| 2026-02-20 | 4 | 4 | 0001193125-26-061385 | 5386 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051548 | 8772 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051530 | 8761 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051545 | 8734 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051528 | 7395 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051525 | 8742 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051520 | 8742 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051537 | 10710 | ||||||
| 2026-02-13 | 5 | 5 | 0001193125-26-051517 | 8732 | ||||||
| 2026-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-015247 | 005-91005 | 26633366 | 34 | 10350 | |||
| 2026-02-13 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001072613-26-000150 | 005-91005 | 26632561 | 34 | 106237 | |||
| 2026-02-05 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-26-000550 | 005-91005 | 26602074 | 34 | 11414 | |||
| 2026-01-30 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000102909-26-000259 | 005-91005 | 26582593 | 34 | 6967 | |||
| 2026-01-12 | 4 | 4 | 0001193125-26-010361 | 5388 | ||||||
| 2026-01-12 | 3 | 3 | 0001193125-26-010351 | 21176 | ||||||
| 2025-12-05 | 8-K | 8-K | 5.02 | 0001193125-25-308769 | 001-38886 | 251551323 | 34 | 168781 | 1 | 1 |
| 2025-12-03 | 4 | 4 | 0001193125-25-306729 | 6991 | ||||||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000905148-25-004065 | 005-91005 | 251487798 | 34 | 38069 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001231919-25-000495 | 005-91005 | 251486985 | 34 | 31111 | |||
| 2025-11-13 | S-3ASR | S-3ASR | 0001193125-25-280501 | 333-291517 | 251479730 | 33 | 1748642 | 1 | 1 | |
| 2025-11-13 | 10-Q | 10-Q | 0001193125-25-280166 | 001-38886 | 251478516 | 34 | 10455431 | 1 | 1 | |
| 2025-11-13 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-280149 | 001-38886 | 251478468 | 34 | 364996 | 1 | 1 |
| 2025-10-17 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-25-002719 | 005-91005 | 251401904 | 34 | 10797 | |||
| 2025-10-07 | 144 | xsl144X01/primary_doc.xml | 0001972481-25-000242 | 001-38886 | 251380143 | 33 | 10292 | |||
| 2025-10-03 | 144 | xsl144X01/primary_doc.xml | 0001972481-25-000235 | 001-38886 | 251374915 | 33 | 9105 | |||
| 2025-08-27 | 144 | xsl144X01/primary_doc.xml | 0001972481-25-000182 | 001-38886 | 251266203 | 33 | 4858 | |||
| 2025-08-20 | 8-K | 8-K | 5.02 | 0001563880-25-000005 | 001-38886 | 251237226 | 34 | 166200 | 1 | 1 |
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000905148-25-002998 | 005-91005 | 251221313 | 34 | 40609 | |||
| 2025-08-11 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001072613-25-000533 | 005-91005 | 251203446 | 34 | 106074 | |||
| 2025-08-07 | S-8 | S-8 | 0000950170-25-105074 | 333-289362 | 251194463 | 33 | 305377 | 1 | 1 | |
| 2025-08-07 | 10-Q | 10-Q | 0000950170-25-105066 | 001-38886 | 251194369 | 34 | 10239044 | 1 | 1 | |
| 2025-08-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-105011 | 001-38886 | 251194011 | 34 | 368703 | 1 | 1 |
| 2025-07-09 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-066695 | 005-91005 | 251113664 | 34 | 14923 | |||
| 2025-06-17 | 8-K | 8-K | 5.02,5.07,9.01 | 0000950170-25-087486 | 001-38886 | 251054129 | 34 | 216725 | 1 | 1 |
| 2025-06-13 | 4 | 4 | 0000950170-25-086165 | 5380 | ||||||
| 2025-06-13 | 4 | 4 | 0000950170-25-086112 | 5413 | ||||||
| 2025-06-13 | 4 | 4 | 0000950170-25-086111 | 5466 | ||||||
| 2025-06-13 | 4 | 4 | 0000950170-25-086110 | 5441 | ||||||
| 2025-06-13 | 4 | 4 | 0000950170-25-086109 | 5436 | ||||||
| 2025-06-04 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-25-134913 | 001-38886 | 251023340 | 34 | 460895 | 1 | 1 |
| 2025-06-04 | 424B5 | 424B5 | 0001193125-25-134905 | 333-273030 | 251023266 | 33 | 1350124 | |||
| 2025-06-03 | 4 | 4 | 0000950170-25-080889 | 6194 | ||||||
| 2025-06-03 | 4 | 4 | 0000950170-25-080887 | 6151 | ||||||
| 2025-06-03 | 4 | 4 | 0000950170-25-080886 | 6185 | ||||||
| 2025-06-03 | 4 | 4 | 0000950170-25-080885 | 6190 | ||||||
| 2025-06-03 | 4 | 4 | 0000950170-25-080883 | 6141 | ||||||
| 2025-06-02 | 424B5 | 424B5 | 0001193125-25-133344 | 333-273030 | 251015542 | 33 | 1352220 | |||
| 2025-06-02 | 8-K | 8-K | 8.01 | 0001193125-25-133273 | 001-38886 | 251014845 | 34 | 138200 | 1 | 1 |
| 2025-06-02 | 8-K | 8-K | 8.01 | 0001193125-25-132890 | 001-38886 | 251013317 | 34 | 155131 | 1 | 1 |
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000905148-25-001760 | 005-91005 | 25954314 | 34 | 40574 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-012996 | 005-91005 | 25949478 | 34 | 49310 | |||
| 2025-05-08 | 10-Q | 10-Q | 0000950170-25-067011 | 001-38886 | 25926383 | 34 | 9312668 | 1 | 1 | |
| 2025-05-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-066971 | 001-38886 | 25926235 | 34 | 330508 | 1 | 1 |
| 2025-04-29 | DEFA14A | DEFA14A | 0000950170-25-059693 | 001-38886 | 25883994 | 34 | 2281070 | 1 | 1 | |
| 2025-04-29 | ARS | ARS | 0000950170-25-059635 | 001-38886 | 25883369 | 34 | 5503901 | |||
| 2025-04-29 | DEF 14A | DEF 14A | 0000950170-25-059628 | 001-38886 | 25883299 | 34 | 6500460 | 1 | 1 | |
| 2025-03-26 | 4 | 4 | 0000950170-25-045295 | 8292 | ||||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044436 | 8628 | ||||||
| 2025-03-21 | 144 | xsl144X01/primary_doc.xml | 0001972481-25-000060 | 001-38886 | 25760659 | 33 | 4284 | |||
| 2025-03-20 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001072613-25-000239 | 005-91005 | 25758214 | 34 | 105944 | 1 | 1 | |
| 2025-03-18 | S-8 | S-8 | 0000950170-25-041206 | 333-285879 | 25748583 | 33 | 164095 | |||
| 2025-03-18 | 10-K | 10-K | 0000950170-25-041194 | 001-38886 | 25748469 | 34 | 12906843 | 1 | 1 | |
| 2025-03-18 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-041187 | 001-38886 | 25748390 | 34 | 370085 | 1 | 1 |
| 2025-03-12 | 4 | 4 | 0000950170-25-037886 | 6114 | ||||||
| 2025-03-12 | 4 | 4 | 0000950170-25-037884 | 6161 | ||||||
| 2025-03-12 | 4 | 4 | 0000950170-25-037883 | 6128 | ||||||
| 2025-03-12 | 4 | 4 | 0000950170-25-037882 | 6171 | ||||||
| 2025-03-12 | 4 | 4 | 0000950170-25-037880 | 21713 | ||||||
| 2025-03-10 | 8-K | 8-K | 8.01 | 0000950170-25-036503 | 001-38886 | 25724672 | 34 | 180735 | 1 | 1 |
| 2025-03-10 | 144 | xsl144X01/primary_doc.xml | 0001972481-25-000049 | 001-38886 | 25724240 | 33 | 4968 | |||
| 2025-02-20 | 4 | 4 | 0000950170-25-024117 | 5383 | ||||||
| 2025-02-20 | 4 | 4 | 0000950170-25-024116 | 5382 | ||||||
| 2025-02-20 | 4 | 4 | 0000950170-25-024114 | 5421 | ||||||
| 2025-02-20 | 4 | 4 | 0000950170-25-024111 | 5416 | ||||||
| 2025-02-20 | 4 | 4 | 0000950170-25-024110 | 5369 | ||||||
| 2025-02-20 | 4 | 4 | 0000950170-25-024109 | 5427 | ||||||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-004225 | 005-91005 | 25631532 | 34 | 31277 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-003984 | 005-91005 | 25625039 | 34 | 52656 | |||
| 2025-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-012911 | 005-91005 | 25620011 | 34 | 10685 | |||
| 2025-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001622627-25-000012 | 005-91005 | 25619025 | 34 | 13565 | |||
| 2025-01-10 | 4 | 4 | 0000950170-25-004164 | 10364 | ||||||
| 2025-01-08 | 8-K | 8-K | 2.02,8.01,9.01 | 0000950170-25-003286 | 001-38886 | 25516602 | 34 | 249895 | 1 | 1 |
| 2024-12-17 | 4 | 4 | 0000950170-24-137255 | 7004 | ||||||
| 2024-12-16 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-24-279715 | 001-38886 | 241552852 | 34 | 452800 | 1 | 1 |
| 2024-12-16 | 424B5 | 424B5 | 0001193125-24-279709 | 333-273030 | 241552821 | 33 | 1268426 | |||
| 2024-12-12 | 8-K | 8-K | 8.01 | 0000950170-24-135602 | 001-38886 | 241543292 | 34 | 169614 | 1 | 1 |
| 2024-12-03 | 8-K | 8-K | 8.01 | 0000950170-24-132883 | 001-38886 | 241523758 | 34 | 205632 | 1 | 1 |
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001104659-24-119338 | 005-91005 | 241464803 | 34 | 249270 | |||
| 2024-11-13 | SC 13G/A | SC 13G/A | 0001104659-24-117756 | 005-91005 | 241454868 | 34 | 73984 | |||
| 2024-11-08 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS, INC. -- SCHEDULE 13D/A( | 0001072613-24-000813 | 005-91005 | 241442478 | 34 | 514958 | |||
| 2024-11-06 | 10-Q | 10-Q | 0000950170-24-122355 | 001-38886 | 241431328 | 34 | 9062784 | 1 | 1 | |
| 2024-11-06 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-122316 | 001-38886 | 241431075 | 34 | 334580 | 1 | 1 |
| 2024-11-06 | SC 13G/A | SC 13G/A | 0001193125-24-251791 | 005-91005 | 241429577 | 34 | 266916 | |||
| 2024-10-23 | SC 13G/A | trvi_13ga_03_sep24.htm | 0001622627-24-000053 | 005-91005 | 241388959 | 34 | 91298 | |||
| 2024-10-21 | 8-K | 8-K | 8.01 | 0000950170-24-115800 | 001-38886 | 241382303 | 34 | 164889 | 1 | 1 |
| 2024-10-04 | 8-K | 8-K | 8.01 | 0000950170-24-112729 | 001-38886 | 241353539 | 34 | 167673 | 1 | 1 |
| 2024-10-01 | 4 | 4 | 0000950170-24-110921 | 5390 | ||||||
| 2024-10-01 | 8-K | 8-K | 5.02,9.01 | 0000950170-24-110462 | 001-38886 | 241340634 | 34 | 234501 | 1 | 1 |
| 2024-09-09 | 4 | 4 | 0000950170-24-104804 | 13911 | ||||||
| 2024-09-05 | 4 | 4 | 0000950170-24-104061 | 19179 | ||||||
| 2024-09-03 | 144 | xsl144X01/primary_doc.xml | 0001972481-24-000217 | 001-38886 | 241274616 | 33 | 4281 | |||
| 2024-08-29 | 4 | 4 | 0000950170-24-101926 | 8648 | ||||||
| 2024-08-27 | 144 | xsl144X01/primary_doc.xml | 0001972481-24-000213 | 001-38886 | 241249110 | 33 | 4327 | |||
| 2024-08-21 | 4 | 4 | 0000950170-24-099481 | 8674 | ||||||
| 2024-08-16 | 4 | 4 | 0000950170-24-098117 | 18843 | ||||||
| 2024-08-15 | 144/A | xsl144X01/primary_doc.xml | 0001972481-24-000199 | 001-38886 | 241213411 | 33 | 5120 | |||
| 2024-08-15 | 144 | xsl144X01/primary_doc.xml | 0001972481-24-000198 | 001-38886 | 241212740 | 33 | 4281 | |||
| 2024-08-08 | 10-Q | 10-Q | 0000950170-24-093983 | 001-38886 | 241188490 | 34 | 8706227 | 1 | 1 | |
| 2024-08-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-093942 | 001-38886 | 241188342 | 34 | 336508 | 1 | 1 |
| 2024-07-11 | SC 13G/A | trvi_13ga_02_jul24.htm | 0001622627-24-000043 | 005-91005 | 241112842 | 34 | 91102 | |||
| 2024-07-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001040197-24-000005 | 005-91005 | 241110144 | 34 | 6291 | |||
| 2024-06-14 | 4 | 4 | 0000950170-24-073751 | 33013 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073728 | 5402 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073727 | 5473 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073726 | 5447 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073736 | 5448 | ||||||
| 2024-06-14 | 4 | 4 | 0000950170-24-073725 | 5420 | ||||||
| 2024-06-13 | 8-K | 8-K | 5.07,9.01 | 0000950170-24-073129 | 001-38886 | 241042039 | 34 | 181553 | 1 | 1 |
| 2024-05-31 | 4 | 4 | 0000950170-24-067305 | 9119 | ||||||
| 2024-05-29 | 144 | xsl144X01/primary_doc.xml | 0001972481-24-000130 | 001-38886 | 24998866 | 33 | 4280 | |||
| 2024-05-24 | 4 | 4 | 0000950170-24-064598 | 9131 | ||||||
| 2024-05-22 | 4 | 4 | 0000950170-24-063531 | 8647 | ||||||
| 2024-05-21 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS, INC. -- SCHEDULE 13D/A( | 0001072613-24-000518 | 005-91005 | 24971164 | 34 | 537548 | |||
| 2024-05-14 | 4 | 4 | 0000950170-24-059722 | 8335 | ||||||
| 2024-05-07 | 10-Q | 10-Q | 0000950170-24-054489 | 001-38886 | 24921949 | 34 | 7927923 | 1 | 1 | |
| 2024-05-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-054478 | 001-38886 | 24921891 | 34 | 304995 | 1 | 1 |
| 2024-04-29 | ARS | ARS | 0000950170-24-049310 | 001-38886 | 24885748 | 34 | 3432644 | |||
| 2024-04-26 | DEFA14A | DEFA14A | 0000950170-24-049247 | 001-38886 | 24884641 | 34 | 521805 | |||
| 2024-04-26 | DEF 14A | DEF 14A | 0000950170-24-049234 | 001-38886 | 24884561 | 34 | 1435341 | |||
| 2024-04-25 | SC 13G/A | TRVI_13GA01 | 0001622627-24-000027 | 005-91005 | 24878207 | 34 | 90270 | |||
| 2024-03-20 | S-8 | S-8 | 0000950170-24-034171 | 333-278101 | 24767913 | 33 | 164540 | |||
| 2024-03-20 | 10-K | 10-K | 0000950170-24-034167 | 001-38886 | 24767885 | 34 | 11221568 | 1 | 1 | |
| 2024-03-20 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-034159 | 001-38886 | 24767848 | 34 | 338929 | 1 | 1 |
| 2024-02-16 | 4 | 4 | 0000950170-24-016469 | 5430 | ||||||
| 2024-02-16 | 4 | 4 | 0000950170-24-016465 | 5424 | ||||||
| 2024-02-16 | 4 | 4 | 0000950170-24-016464 | 5368 | ||||||
| 2024-02-16 | 4 | 4 | 0000950170-24-016462 | 5372 | ||||||
| 2024-02-16 | 4 | 4 | 0000950170-24-016460 | 5386 | ||||||
| 2024-02-16 | 4 | 4 | 0000950170-24-016458 | 5419 | ||||||
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001104659-24-024225 | 005-91005 | 24641693 | 34 | 239068 | |||
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001104659-24-023539 | 005-91005 | 24637128 | 34 | 103507 | |||
| 2024-02-14 | SC 13G/A | sayw24021419_13ga.htm | 0000905148-24-000622 | 005-91005 | 24633646 | 34 | 381904 | |||
| 2024-02-12 | SC 13G/A | SC 13G/A | 0001104659-24-013565 | 005-91005 | 24617222 | 34 | 70838 | |||
| 2023-11-09 | 10-Q | 10-Q | 0000950170-23-062063 | 001-38886 | 231392570 | 34 | 10610453 | 1 | 1 | |
| 2023-11-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-062031 | 001-38886 | 231392406 | 34 | 368134 | 1 | 1 |
| 2023-10-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-052687 | 9170 | ||||||
| 2023-09-13 | 4 | FORM 4 SUBMISSION | 0001209191-23-049252 | 9172 | ||||||
| 2023-09-11 | 144 | xsl144X01/primary_doc.xml | 0001972481-23-000081 | 001-38886 | 231247756 | 33 | 5682 | |||
| 2023-08-15 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-08-15 16:00:00 | 9999999995-23-002394 | 333-273030 | 231176401 | 33 | 1714 | ||
| 2023-08-14 | CORRESP | filename1.htm | 0001193125-23-212303 | 6514 | ||||||
| 2023-08-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-045595 | 9169 | ||||||
| 2023-08-11 | S-3/A | S-3/A | 0001193125-23-210712 | 333-273030 | 231164053 | 33 | 1349718 | |||
| 2023-08-10 | 10-Q | 10-Q | 0000950170-23-041318 | 001-38886 | 231159416 | 34 | 12067589 | 1 | 1 | |
| 2023-08-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-041312 | 001-38886 | 231159375 | 34 | 400115 | 1 | 1 |
| 2023-07-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-042078 | 9167 | ||||||
| 2023-07-05 | UPLOAD | filename1.pdf | 0000000000-23-007069 | 40247 | ||||||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040303 | 5543 | ||||||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040289 | 5548 | ||||||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040288 | 5619 | ||||||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040287 | 5593 | ||||||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040291 | 5566 | ||||||
| 2023-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-23-040290 | 5594 | ||||||
| 2023-06-29 | S-3 | S-3 | 0001193125-23-178727 | 333-273030 | 231058326 | 33 | 2372535 | |||
| 2023-06-29 | 8-K | 8-K | 5.03,5.07,9.01 | 0000950170-23-030725 | 001-38886 | 231057336 | 34 | 247443 | 1 | 1 |
| 2023-06-21 | 4 | FORM 4 SUBMISSION | 0001209191-23-038744 | 7132 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037029 | 9167 | ||||||
| 2023-06-12 | 144 | xsl144X01/primary_doc.xml | 0001972481-23-000023 | 001-38886 | 231008775 | 33 | 5519 | |||
| 2023-05-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-029399 | 9165 | ||||||
| 2023-05-11 | S-8 | S-8 | 0000950170-23-021261 | 333-271839 | 23911280 | 33 | 217358 | |||
| 2023-05-11 | 10-Q | 10-Q | 0000950170-23-021240 | 001-38886 | 23911132 | 34 | 10655924 | 1 | 1 | |
| 2023-05-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-021229 | 001-38886 | 23911054 | 34 | 359347 | 1 | 1 |
| 2023-05-01 | ARS | ARS | 0000950170-23-016230 | 001-38886 | 23873492 | 34 | 2565372 | |||
| 2023-05-01 | DEFA14A | DEFA14A | 0000950170-23-016227 | 001-38886 | 23873480 | 34 | 1210696 | |||
| 2023-05-01 | DEF 14A | DEF 14A | 0000950170-23-016226 | 001-38886 | 23873468 | 34 | 1694157 | |||
| 2023-04-14 | PRE 14A | PRE 14A | 0000950170-23-012903 | 001-38886 | 23821497 | 34 | 1695958 | |||
| 2023-04-14 | 8-K | 8-K | 5.03,9.01 | 0000950170-23-012870 | 001-38886 | 23821075 | 34 | 451742 | 1 | 1 |
| 2023-04-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-024115 | 9168 | ||||||
| 2023-04-11 | 144 | xsl144X01/primary_doc.xml | 0001972481-23-000001 | 001-38886 | 23812789 | 33 | 5600 | |||
| 2023-03-16 | 10-K | 10-K | 0000950170-23-008472 | 001-38886 | 23738965 | 34 | 14872980 | 1 | 1 | |
| 2023-03-16 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-008459 | 001-38886 | 23738888 | 34 | 410922 | 1 | 1 |
| 2023-03-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-018875 | 9304 | ||||||
| 2023-03-08 | 4 | FORM 4 SUBMISSION | 0001209191-23-017148 | 7102 | ||||||
| 2023-02-16 | 4 | FORM 4 SUBMISSION | 0001209191-23-010202 | 5519 | ||||||
| 2023-02-16 | 4 | FORM 4 SUBMISSION | 0001209191-23-010190 | 5538 | ||||||
| 2023-02-16 | 3 | FORM 3 SUBMISSION | 0001209191-23-010184 | 12169 | ||||||
| 2023-02-16 | 4 | FORM 4 SUBMISSION | 0001209191-23-010177 | 5500 | ||||||
| 2023-02-16 | 4 | FORM 4 SUBMISSION | 0001209191-23-010165 | 5533 | ||||||
| 2023-02-16 | 4 | FORM 4 SUBMISSION | 0001209191-23-010152 | 5487 | ||||||
| 2023-02-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-009694 | 9271 | ||||||
| 2023-02-15 | SC 13G | TREVI SC 13GA | 0001622627-23-000007 | 005-91005 | 23634735 | 34 | 91726 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001104659-23-021871 | 005-91005 | 23631007 | 34 | 251981 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001104659-23-021440 | 005-91005 | 23628180 | 34 | 120637 | |||
| 2023-02-14 | SC 13G/A | armistice-trvi123122a1.htm | 0001172661-23-001186 | 005-91005 | 23626565 | 34 | 90641 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001140361-23-006815 | 005-91005 | 23626289 | 34 | 380012 | |||
| 2023-02-10 | SC 13G/A | AMENDMENT TO FORM SC 13G | 0001387131-23-001761 | 005-91005 | 23612397 | 34 | 85394 | |||
| 2023-02-10 | SC 13G | SC 13G | 0001104659-23-018476 | 005-91005 | 23611633 | 34 | 77331 | |||
| 2022-11-14 | 4 | FORM 4 SUBMISSION | 0001209191-22-056635 | 5484 | ||||||
| 2022-11-14 | 3 | FORM 3 SUBMISSION | 0001209191-22-056620 | 7307 | ||||||
| 2022-11-10 | 10-Q | 10-Q | 0001564590-22-037385 | 001-38886 | 221377263 | 34 | 9429354 | 1 | 1 | |
| 2022-11-10 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-037382 | 001-38886 | 221377149 | 34 | 359647 | 1 | 1 |
| 2022-10-07 | SC 13G | SC 13G | 0001140361-22-036678 | 005-91005 | 221301575 | 34 | 392693 | |||
| 2022-10-07 | SC 13G/A | SC 13G/A | 0001193125-22-259524 | 005-91005 | 221300445 | 34 | 253171 | |||
| 2022-09-23 | 424B5 | 424B5 | 0001193125-22-250276 | 333-239499 | 221263053 | 33 | 600499 | |||
| 2022-09-23 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-22-249748 | 001-38886 | 221260786 | 34 | 627132 | 1 | 1 |
| 2022-09-22 | 424B5 | 424B5 | 0001193125-22-249167 | 333-239499 | 221259306 | 33 | 603423 | |||
| 2022-09-19 | 4 | FORM 4 SUBMISSION | 0001209191-22-050525 | 6023 | ||||||
| 2022-09-19 | 4 | FORM 4 SUBMISSION | 0001209191-22-050521 | 6018 | ||||||
| 2022-09-19 | 8-K | 8-K | 8.01,9.01 | 0001564590-22-031834 | 001-38886 | 221249379 | 34 | 11153769 | 1 | 1 |
| 2022-08-11 | 10-Q | 10-Q | 0001564590-22-029142 | 001-38886 | 221156435 | 34 | 9359697 | 1 | 1 | |
| 2022-08-11 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-029123 | 001-38886 | 221155975 | 34 | 368631 | 1 | 1 |
| 2022-07-06 | 4 | CHANGES IN BENEFICIAL OWNERSHIP | 0001387131-22-007483 | 14907 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040302 | 10294 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040298 | 10293 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040296 | 10329 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040294 | 10278 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040292 | 10252 | ||||||
| 2022-07-01 | 4 | FORM 4 SUBMISSION | 0001209191-22-040290 | 6271 | ||||||
| 2022-07-01 | 4 | FORM 4 SUBMISSION | 0001209191-22-040287 | 6320 | ||||||
| 2022-07-01 | 4 | FORM 4 SUBMISSION | 0001209191-22-040284 | 6266 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040277 | 10242 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040273 | 10288 | ||||||
| 2022-07-01 | 4/A | FORM 4/A SUBMISSION | 0001209191-22-040268 | 10231 | ||||||
| 2022-07-01 | 4 | CHANGES IN BENEFICIAL OWNERSHIP | 0001387131-22-007443 | 14842 | ||||||
| 2022-06-29 | 8-K | 8-K | 8.01 | 0001564590-22-024605 | 001-38886 | 221051816 | 34 | 179212 | 1 | 1 |
| 2022-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-038976 | 5511 | ||||||
| 2022-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-038967 | 5562 | ||||||
| 2022-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-038958 | 5561 | ||||||
| 2022-06-23 | 8-K | 8-K | 5.07 | 0001564590-22-024091 | 001-38886 | 221036070 | 34 | 189226 | 1 | 1 |
| 2022-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-038920 | 5587 | ||||||
| 2022-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-038906 | 5534 | ||||||
| 2022-06-23 | 4 | FORM 4 SUBMISSION | 0001209191-22-038901 | 5516 | ||||||
| 2022-05-16 | 424B5 | 424B5 | 0001564590-22-020201 | 333-239499 | 22924501 | 33 | 644630 | |||
| 2022-05-16 | 8-K | 8-K | 1.01,9.01 | 0001564590-22-020177 | 001-38886 | 22924252 | 34 | 301267 | 1 | 1 |
| 2022-05-12 | 10-Q | 10-Q | 0001564590-22-019895 | 001-38886 | 22918435 | 34 | 7237654 | 1 | 1 | |
| 2022-05-12 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-019858 | 001-38886 | 22917891 | 34 | 331809 | 1 | 1 |
| 2022-05-11 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-05-11 16:00:00 | 9999999995-22-001421 | 333-264614 | 22915509 | 33 | 1713 | ||
| 2022-05-09 | CORRESP | filename1.htm | 0001564590-22-018916 | 6662 | ||||||
| 2022-05-06 | UPLOAD | filename1.pdf | 0000000000-22-005009 | 40205 | ||||||
| 2022-05-04 | 4 | xslF345X03/ownership.xml | 0001387131-22-005711 | 12059 | ||||||
| 2022-05-02 | 4 | CHANGES IN BENEFICIAL OWNERSHIP | 0001387131-22-005629 | 14835 | ||||||
| 2022-05-02 | S-8 | S-8 | 0001564590-22-017068 | 333-264615 | 22882346 | 33 | 288838 | |||
| 2022-05-02 | S-3 | S-3 | 0001564590-22-017057 | 333-264614 | 22882187 | 33 | 661989 | |||
| 2022-05-02 | DEFA14A | DEFA14A | 0001564590-22-016913 | 001-38886 | 22879249 | 34 | 447508 | |||
| 2022-04-29 | DEF 14A | DEF 14A | 0001564590-22-016859 | 001-38886 | 22877804 | 34 | 1264062 | |||
| 2022-04-25 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS -- SCHEDULE 13D/A3 | 0001072613-22-000390 | 005-91005 | 22850501 | 34 | 609070 | |||
| 2022-04-21 | SC 13G | SC 13G | 0001104659-22-048379 | 005-91005 | 22841437 | 34 | 300124 | |||
| 2022-04-21 | SC 13G | SC 13G | 0001104659-22-048154 | 005-91005 | 22839965 | 34 | 100153 | |||
| 2022-04-18 | D | xslFormDX01/primary_doc.xml | 06b | 0001563880-22-000001 | 021-442332 | 22832669 | 33 | 17050 | ||
| 2022-04-18 | SC 13G | SC 13G | 0001193125-22-107726 | 005-91005 | 22831741 | 34 | 290511 | |||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024323 | 8669 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024322 | 10980 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024321 | 10942 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024320 | 10850 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024319 | 10944 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024318 | 10982 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024315 | 10934 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024314 | 10946 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024307 | 5264 | ||||||
| 2022-04-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-024301 | 8682 | ||||||
| 2022-04-08 | SC 13G | MAI 13G | 0001040197-22-000003 | 005-91005 | 22815850 | 34 | 300223 | |||
| 2022-04-07 | 8-K | 8-K | 1.01,3.02,8.01,9.01 | 0001193125-22-098229 | 001-38886 | 22812349 | 34 | 785549 | 1 | 1 |
| 2022-03-17 | 10-K | 10-K | 0001564590-22-010875 | 001-38886 | 22748923 | 34 | 10601554 | 1 | 1 | |
| 2022-03-17 | 8-K | 8-K | 2.02,9.01 | 0001564590-22-010864 | 001-38886 | 22748555 | 34 | 369318 | 1 | 1 |
| 2022-03-16 | 8-K | 8-K | 8.01 | 0001564590-22-010637 | 001-38886 | 22744886 | 34 | 170049 | 1 | 1 |
| 2022-03-09 | SC 13G | SC 13G | 0001019056-22-000268 | 005-91005 | 22726231 | 34 | 143936 | |||
| 2022-03-09 | SC 13G | SC 13G | 0001104659-22-031938 | 005-91005 | 22724403 | 34 | 83837 | |||
| 2022-02-24 | 8-K | 8-K | 8.01 | 0001564590-22-006498 | 001-38886 | 22666536 | 34 | 239602 | 1 | 1 |
| 2022-02-15 | 4 | FORM 4 SUBMISSION | 0001209191-22-009743 | 5498 | ||||||
| 2022-02-15 | 4 | FORM 4 SUBMISSION | 0001209191-22-009739 | 5520 | ||||||
| 2022-02-15 | 4 | FORM 4 SUBMISSION | 0001209191-22-009738 | 5534 | ||||||
| 2022-02-15 | 4 | FORM 4 SUBMISSION | 0001209191-22-009734 | 5547 | ||||||
| 2022-02-15 | 4 | FORM 4 SUBMISSION | 0001209191-22-009733 | 5489 | ||||||
| 2022-02-14 | SC 13G | SC 13G | 0001193125-22-042215 | 005-91005 | 22634802 | 34 | 69993 | |||
| 2022-02-11 | SC 13G/A | AMENDMENT TO FORM SC 13G | 0001387131-22-001690 | 005-91005 | 22621157 | 34 | 118870 | |||
| 2022-02-01 | 8-K | 8-K | 8.01 | 0001564590-22-003250 | 001-38886 | 22576928 | 34 | 174926 | 1 | 1 |
| 2022-01-26 | SC 13G/A | SC 13G/A | 0001193125-22-018305 | 005-91005 | 22558082 | 34 | 47235 | |||
| 2022-01-21 | 3 | FORM 3 - TREVI THERAPEUTICS INC. | 0001387131-22-000606 | 9099 | ||||||
| 2022-01-14 | 8-K | 8-K | 3.01 | 0001564590-22-001365 | 001-38886 | 22532227 | 34 | 173399 | 1 | 1 |
| 2022-01-05 | 8-K | 8-K | 8.01 | 0001564590-22-000348 | 001-38886 | 22509421 | 34 | 174330 | 1 | 1 |
| 2021-11-16 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-11-16 16:00:00 | 9999999995-21-004369 | 333-260820 | 211418307 | 33 | 1714 | ||
| 2021-11-12 | CORRESP | filename1.htm | 0001193125-21-328039 | 5035 | ||||||
| 2021-11-10 | 10-Q | 10-Q | 0001564590-21-056183 | 001-38886 | 211396644 | 34 | 7916402 | 1 | 1 | |
| 2021-11-10 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-056180 | 001-38886 | 211396589 | 34 | 361072 | 1 | 1 |
| 2021-11-10 | UPLOAD | filename1.pdf | 0000000000-21-013643 | 40210 | ||||||
| 2021-11-05 | S-3 | S-3 | 0001193125-21-321577 | 333-260820 | 211384436 | 33 | 254121 | |||
| 2021-11-02 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS -- SCHEDULE 13D/A2 | 0001072613-21-000615 | 005-91005 | 211369491 | 34 | 407908 | |||
| 2021-10-25 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-10-25 16:00:00 | 9999999995-21-004024 | 333-260279 | 211345810 | 33 | 1714 | ||
| 2021-10-21 | D | xslFormDX01/primary_doc.xml | 06b | 0001563880-21-000003 | 021-418073 | 211337275 | 33 | 13412 | ||
| 2021-10-21 | CORRESP | filename1.htm | 0001193125-21-303975 | 5073 | ||||||
| 2021-10-21 | UPLOAD | filename1.pdf | 0000000000-21-012778 | 40196 | ||||||
| 2021-10-20 | D | xslFormDX01/primary_doc.xml | 06b | 0001563880-21-000001 | 021-417806 | 211334157 | 33 | 15224 | ||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061098 | 10419 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061097 | 10381 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061096 | 10289 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061095 | 10383 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061094 | 10421 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061093 | 10373 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061092 | 10385 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061091 | 10287 | ||||||
| 2021-10-19 | 4 | FORM 4 SUBMISSION | 0001209191-21-061090 | 13489 | ||||||
| 2021-10-19 | 8-K | 8-K | 1.01,3.02,8.01,9.01 | 0001193125-21-301603 | 001-38886 | 211329687 | 34 | 756989 | 1 | 1 |
| 2021-10-15 | S-3 | S-3 | 0001193125-21-300007 | 333-260279 | 211326064 | 33 | 262350 | |||
| 2021-10-08 | RW | RW | 0001193125-21-295518 | 333-259120 | 211315637 | NE | 7479 | |||
| 2021-10-01 | 8-K | 8-K | 1.01,3.02,8.01,9.01 | 0001193125-21-288912 | 001-38886 | 211297187 | 34 | 937207 | 1 | 1 |
| 2021-08-27 | S-1 | S-1 | 0001193125-21-259333 | 333-259120 | 211218932 | 33 | 451375 | |||
| 2021-08-12 | 10-Q | 10-Q | 0001564590-21-043968 | 001-38886 | 211167610 | 34 | 7522704 | 1 | 1 | |
| 2021-08-12 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-043962 | 001-38886 | 211167535 | 34 | 346199 | 1 | 1 |
| 2021-08-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-050440 | 5526 | ||||||
| 2021-08-09 | 3 | FORM 3 SUBMISSION | 0001209191-21-050436 | 7375 | ||||||
| 2021-08-09 | 8-K | 8-K | 5.07 | 0001564590-21-042744 | 001-38886 | 211157609 | 34 | 174022 | 1 | 1 |
| 2021-07-14 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2021-07-14 16:00:00 | 9999999995-21-002767 | 333-257747 | 211091578 | 33 | 1714 | ||
| 2021-07-14 | 424B3 | 424B3 | 0001193125-21-215367 | 333-257747 | 211090812 | 33 | 263562 | |||
| 2021-07-12 | CORRESP | filename1.htm | 0001193125-21-213070 | 6171 | ||||||
| 2021-07-09 | UPLOAD | filename1.pdf | 0000000000-21-008505 | 40186 | ||||||
| 2021-07-09 | 8-K | 8-K | 8.01,9.01 | 0001193125-21-211342 | 001-38886 | 211081725 | 34 | 12353416 | 1 | 1 |
| 2021-07-07 | S-1 | S-1 | 0001193125-21-209928 | 333-257747 | 211077889 | 33 | 386220 | |||
| 2021-07-07 | S-8 | S-8 | 0001193125-21-208997 | 333-257729 | 211076043 | 33 | 50636 | |||
| 2021-07-07 | 8-K | 8-K | 1.01,9.01 | 0001564590-21-035888 | 001-38886 | 211075307 | 34 | 281659 | 1 | 1 |
| 2021-06-21 | 8-K | 8-K | 5.07 | 0001564590-21-033643 | 001-38886 | 211031221 | 34 | 196538 | 1 | 1 |
| 2021-06-21 | 8-K | 8-K | 1.01,3.02,9.01 | 0001193125-21-195073 | 001-38886 | 211030753 | 34 | 294215 | ||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041537 | 5511 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041393 | 5558 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041391 | 5583 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041392 | 5512 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041389 | 5530 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041388 | 5557 | ||||||
| 2021-05-13 | 10-Q | 10-Q | 0001564590-21-027550 | 001-38886 | 21919742 | 34 | 5667327 | 1 | ||
| 2021-05-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-027538 | 001-38886 | 21919636 | 34 | 138319 | ||
| 2021-04-27 | DEFA14A | DEFA14A | 0001193125-21-134266 | 001-38886 | 21859160 | 34 | 290487 | |||
| 2021-04-27 | DEF 14A | DEF 14A | 0001193125-21-134252 | 001-38886 | 21859099 | 34 | 745943 | |||
| 2021-04-15 | 4 | FORM 4 SUBMISSION | 0000899243-21-016010 | 5540 | ||||||
| 2021-04-15 | 3 | FORM 3 SUBMISSION | 0000899243-21-016007 | 7639 | ||||||
| 2021-04-02 | 8-K | 8-K | 5.02 | 0001193125-21-105160 | 001-38886 | 21802142 | 34 | 19763 | ||
| 2021-03-25 | 10-K | 10-K | 0001564590-21-015506 | 001-38886 | 21772636 | 34 | 9678994 | 1 | ||
| 2021-03-25 | 8-K | 8-K | 2.02,9.01 | 0001193125-21-094442 | 001-38886 | 21772470 | 34 | 66563 | ||
| 2021-03-22 | 8-K | 8-K | 5.02 | 0001193125-21-089553 | 001-38886 | 21761468 | 34 | 18617 | ||
| 2021-02-19 | 4 | FORM 4 SUBMISSION | 0000899243-21-007378 | 5536 | ||||||
| 2021-02-19 | 4 | FORM 4 SUBMISSION | 0000899243-21-007380 | 5480 | ||||||
| 2021-02-19 | 4 | FORM 4 SUBMISSION | 0000899243-21-007377 | 5486 | ||||||
| 2021-02-19 | 4 | FORM 4 SUBMISSION | 0000899243-21-007379 | 5561 | ||||||
| 2021-02-12 | SC 13G/A | AMENDMENT TO FORM SC 13G | 0001387131-21-002276 | 005-91005 | 21628896 | 34 | 77450 | |||
| 2021-02-03 | 4 | FORM 4 SUBMISSION | 0000899243-21-004682 | 5537 | ||||||
| 2021-02-03 | 3 | FORM 3 SUBMISSION | 0000899243-21-004679 | 7488 | ||||||
| 2020-11-12 | 10-Q | 10-Q | 0001564590-20-053330 | 001-38886 | 201303760 | 34 | 7177294 | 1 | ||
| 2020-11-12 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-053328 | 001-38886 | 201303732 | 34 | 163584 | ||
| 2020-10-21 | 8-K | 8-K | 8.01 | 0001193125-20-273348 | 001-38886 | 201249646 | 34 | 17724 | ||
| 2020-09-11 | 8-K | 8-K | 5.02 | 0001193125-20-244116 | 001-38886 | 201171075 | 34 | 17538 | ||
| 2020-08-13 | 10-Q | 10-Q | 0001564590-20-040031 | 001-38886 | 201099534 | 34 | 6262361 | 1 | ||
| 2020-08-13 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-040019 | 001-38886 | 201099403 | 34 | 159431 | ||
| 2020-07-13 | 8-K | 8-K | 8.01 | 0001193125-20-191517 | 001-38886 | 201024311 | 34 | 22311 | ||
| 2020-07-02 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2020-07-02 16:00:00 | 9999999995-20-001643 | 333-239499 | 201011981 | 33 | 1714 | ||
| 2020-07-02 | 424B3 | 424B3 | 0001193125-20-186869 | 333-239499 | 201009740 | 33 | 189418 | |||
| 2020-07-01 | 4 | FORM 4 SUBMISSION | 0000899243-20-018159 | 5689 | ||||||
| 2020-07-01 | 3 | FORM 3 SUBMISSION | 0000899243-20-018153 | 7539 | ||||||
| 2020-06-30 | UPLOAD | filename1.pdf | 0000000000-20-005874 | 40281 | ||||||
| 2020-06-30 | 8-K | 8-K | 5.02,9.01 | 0001193125-20-184038 | 001-38886 | 201002502 | 34 | 39900 | ||
| 2020-06-30 | CORRESP | filename1.htm | 0001193125-20-184009 | 5729 | ||||||
| 2020-06-26 | S-3 | S-3 | 0001193125-20-181094 | 333-239499 | 20994918 | 33 | 1529589 | |||
| 2020-06-17 | 8-K | 8-K | 5.02,5.07 | 0001193125-20-171372 | 001-38886 | 20970080 | 34 | 22176 | ||
| 2020-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-20-036666 | 5510 | ||||||
| 2020-06-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-016536 | 5557 | ||||||
| 2020-06-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-016532 | 5582 | ||||||
| 2020-06-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-016530 | 5556 | ||||||
| 2020-05-29 | DEFA14A | DEFA14A | 0001193125-20-155814 | 001-38886 | 20928162 | 34 | 50761 | |||
| 2020-05-07 | 10-Q | 10-Q | 0001564590-20-022893 | 001-38886 | 20856791 | 34 | 4825366 | 1 |
One latest value per concept from companyfacts (247 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 142.56M | 2026-10-31 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 588.40M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 5.42M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-21 | 0001193125-26-166695 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 1.50M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-21 | 0001193125-26-166695 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | 15.38M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-21 | 0001193125-26-166695 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 3.94M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-21 | 0001193125-26-166695 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 648.7 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-21 | 0001193125-26-166695 | ||
| ffd | NetFeeAmt | NetFeeAmt | USD | 19,853.2 | 2026-08-06 | S-8 | 2026-08-06 | 0001193125-26-338071 | |||
| ffd | NrrtvMaxAggtOfferingPric | NrrtvMaxAggtOfferingPric | USD | 173.42M | 2026-04-17 | 424B5 | 2026-04-17 | 0001193125-26-161582 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 19,853.26 | 2026-08-06 | S-8 | 2026-08-06 | 0001193125-26-338071 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 143.76M | 2026-08-06 | S-8 | 2026-08-06 | 0001193125-26-338071 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-08-06 | S-8 | 2026-08-06 | 0001193125-26-338071 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-04-17 | 424B5 | 2026-04-17 | 0001193125-26-161582 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 1.51M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 1.86M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | AccruedEmployeeBenefitsCurrent | Accrued Employee Benefits, Current | USD | 2.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 6.02M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 787,000 | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-13 | 0001564590-20-040031 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 359,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -1.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 686.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | USD | -2.24M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 8.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | AmortizationOfFinancingCostsAndDiscounts | Amortization of Debt Issuance Costs and Discounts | USD | 180,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 13.38M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | Assets | Assets | USD | 310.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 305.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 2,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 1.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 273.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AvailableForSaleDebtSecuritiesGrossUnrealizedLoss | Debt Securities, Available-for-sale, Unrealized Loss | USD | 126,000 | 2023-01-01 | 2023-06-30 | 2023 | Q2 | 10-Q | 2023-08-10 | 0000950170-23-041318 |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | USD | 18.14M | 2024-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | USD | 18.14M | 2024-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | USD | 175.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | USD | 174.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 271.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 27.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | 64.19M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-12 | 0001564590-19-031528 |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 27.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 8.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 31.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 400.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 142.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 142.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 143,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -54.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 10.38M | 2019-05-09 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 | |
| us-gaap | CurrentFederalStateAndLocalTaxExpenseBenefit | Current Federal, State and Local, Tax Expense (Benefit) | USD | -64,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | -64,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss | Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss | USD | 1.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | USD | 0 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-07 | 0000950170-24-054489 | |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | Security | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | DebtSecuritiesAvailableForSaleRealizedGainLoss | Debt Securities, Available-for-sale, Realized Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPosition | Debt Securities, Available-for-sale, Unrealized Loss Position | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 183,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 1.53M | 2018-12-31 | 2019 | Q2 | 10-Q | 2019-08-12 | 0001564590-19-031528 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 93.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 64.17M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 3.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 93.69M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | DeferredTaxLiabilitiesOther | Deferred Tax Liabilities, Other | USD | 183,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | DefinedContributionPlanEmployerMatchingContributionPercentOfMatch | Defined Contribution Plan, Employer Matching Contribution, Percent of Match | pure | 0.5 | 2024-01-01 | 2024-01-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 |
| us-gaap | DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage | Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage | pure | 0.25 | 2013-03-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 | |
| us-gaap | Depreciation | Depreciation | USD | 132,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 109,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | DerivativeFairValueOfDerivativeLiability | Derivative Liability, Fair Value, Gross Liability | USD | 196,000 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001564590-22-010875 | |
| us-gaap | DividendsCommonStockCash | Dividends, Common Stock, Cash | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | DividendsPayableCurrentAndNoncurrent | Dividends Payable | USD | 16.20M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-010996 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.34 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.24 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-12 | 0001564590-22-019895 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.34 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.209 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.028 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0.001 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.027 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet | Embedded Derivative, Gain (Loss) on Embedded Derivative, Net | USD | -147,000 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 11.50M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | FinanceLeaseInterestExpense | Finance Lease, Interest Expense | USD | 24,000 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-09 | 0000950170-23-062063 |
| us-gaap | FinanceLeaseLiability | Finance Lease, Liability | USD | 31,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 | |
| us-gaap | FinanceLeaseLiabilityCurrent | Finance Lease, Liability, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | FinanceLeaseLiabilityNoncurrent | Finance Lease, Liability, Noncurrent | USD | 31,000 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDue | Finance Lease, Liability, Payment, Due | USD | 32,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueNextTwelveMonths | Finance Lease, Liability, to be Paid, Year One | USD | 32,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearTwo | Finance Lease, Liability, to be Paid, Year Two | USD | 32,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 | |
| us-gaap | FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear | Finance Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 32,000 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122355 | |
| us-gaap | FinanceLeaseLiabilityUndiscountedExcessAmount | Finance Lease, Liability, Undiscounted Excess Amount | USD | 1,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 | |
| us-gaap | FinanceLeasePrincipalPayments | Finance Lease, Principal Payments | USD | 11,000 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | FinanceLeaseRightOfUseAsset | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | FinanceLeaseWeightedAverageDiscountRatePercent | Finance Lease, Weighted Average Discount Rate, Percent | pure | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | GainLossOnDispositionOfAssets1 | Gain (Loss) on Disposition of Assets | USD | -7,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 15.75M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ImpairmentOfLongLivedAssetsHeldForUse | Impairment of Long-Lived Assets Held-for-use | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008472 |
| us-gaap | ImpairmentOfLongLivedAssetsToBeDisposedOf | Impairment of Long-Lived Assets to be Disposed of | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008472 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -52.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | -33,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | -59,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | IncomeTaxPaidStateAndLocalAfterRefundReceived | IncomeTaxPaidStateAndLocalAfterRefundReceived | USD | -33,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxReceivable | Income Taxes Receivable | USD | 18,000 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-010996 | |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 8.96M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -8.99M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 14,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 1.20M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | -69,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 1.18M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -2.21M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | -433,000 | 2020-01-01 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022893 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 226,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | IncreaseDecreaseInDeferredLeasingFees | Increase (Decrease) in Deferred Leasing Fees | USD | -43,000 | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-010996 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 6.76M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | IncreaseDecreaseInPrepaidExpense | Increase (Decrease) in Prepaid Expense | USD | -449,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | IncreaseDecreaseInSecurityDeposits | Increase (Decrease) in Security Deposits | USD | 33,000 | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-010996 |
| us-gaap | InterestExpense | Interest Expense | USD | 2,000 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-08 | 0000950170-24-093983 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 1.93M | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-08 | 0000950170-24-093983 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 4,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 7.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | LeaseCost | Lease, Cost | USD | 354,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 846,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 371,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 95,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 95,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 380,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 91,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-13 | 0001193125-25-280166 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 93,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | Liabilities | Liabilities | USD | 8.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 310.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 7.87M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | LoansPayableCurrent | Loans Payable, Current | USD | 7.00M | 2022-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 | |
| us-gaap | LongTermLoansPayable | Loans Payable, Noncurrent | USD | 2.15M | 2022-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 | |
| us-gaap | MarketableSecuritiesCurrent | Marketable Securities, Current | USD | 271.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | MarketableSecuritiesNoncurrent | Marketable Securities, Noncurrent | USD | 1.00M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-11 | 0001564590-22-029142 | |
| us-gaap | MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss | USD | 0 | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-07 | 0000950170-24-054489 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 164.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -102.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -53.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -52.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -32.76M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 7.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 59.91M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -59.91M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 342,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 753,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 340,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 187,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 351,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 471,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 308,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 465,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-14 | 0001564590-19-043525 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 24,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-14 | 0001564590-19-043525 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 131,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-14 | 0001564590-19-043525 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 138,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-14 | 0001564590-19-043525 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 138,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-14 | 0001564590-19-043525 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 34,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-14 | 0001564590-19-043525 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.109 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | OperatingLossCarryforwards | Operating Loss Carryforwards | USD | 178.40M | 2022-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 169,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 2.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 4.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | USD | -1.65M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 3,000 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 | |
| us-gaap | OtherNonoperatingExpense | Other Nonoperating Expense | USD | 375,000 | 2021-01-01 | 2021-09-30 | 2022 | Q3 | 10-Q | 2022-11-10 | 0001564590-22-037385 |
| us-gaap | OtherNonoperatingIncome | Other Nonoperating Income | USD | 165,000 | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-11 | 0000950170-23-021240 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -1,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | OtherPrepaidExpenseCurrent | Other Prepaid Expense, Current | USD | 108,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 | |
| us-gaap | OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale | USD | 0 | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-11 | 0000950170-23-021240 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 21,000 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 444,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 209.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 251,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | PreferredStockDividendRatePercentage | Preferred Stock, Dividend Rate, Percentage | pure | 0.06 | 2019-05-08 | 2019-05-09 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | PreferredStockLiquidationPreferenceValue | Preferred Stock, Liquidation Preference, Value | USD | 124.72M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-06-14 | 0001193125-19-172660 | |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 5.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | PreferredStockValueOutstanding | Preferred Stock, Value, Outstanding | USD | 128.15M | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-06-14 | 0001193125-19-172660 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 1.39M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0001564590-21-056183 | |
| us-gaap | PrepaidExpenseCurrent | Prepaid Expense, Current | USD | 3.58M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 1.01M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0001564590-21-056183 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 51.15M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 62.60M | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-06-14 | 0001193125-19-172660 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 9.96M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | ProceedsFromIssuanceOfLongTermDebt | Proceeds from Issuance of Long-term Debt | USD | 14.00M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001564590-22-010875 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 105.41M | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-20 | 0000950170-24-034167 |
| us-gaap | ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | USD | 107.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 2.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 66,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ProceedsFromWarrantExercises | Proceeds from Warrant Exercises | USD | 10.76M | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 537,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 342,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | RedeemablePreferredStockDividends | Redeemable Preferred Stock Dividends | USD | 2.24M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | RepaymentsOfLongTermDebt | Repayments of Long-term Debt | USD | 9.41M | 2023-01-01 | 2023-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122355 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 44.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -382.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability | USD | 242,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-18 | 0000950170-25-041194 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 9,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | SecurityDeposit | Security Deposit | USD | 19,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-12 | 0001564590-20-053330 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 8.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 1.033 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008472 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 1.101 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.98 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.024 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008472 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.044 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 47.57M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 6.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 3.92 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 4.34B | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 344 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 510,978 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 3.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 4.01 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares | 5.28M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | USD/shares | 8.33 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 82.72M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 11.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 5.94 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 4.50M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares | 540,706 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-06-14 | 0001193125-19-172660 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | USD/shares | 2.38 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-06-14 | 0001193125-19-172660 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 2.68 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | USD/shares | 5.95 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 7.01 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 11.25 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | SharePrice | Share Price | USD/shares | 1 | 2013-12-26 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 302.76M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 1 | 2019-01-01 | 2019-03-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 876,664 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 127.50M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 66,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 162.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 2.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | TemporaryEquityAccretionToRedemptionValueAdjustment | Temporary Equity, Accretion to Redemption Value, Adjustment | USD | -1.53M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001564590-21-015506 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 11.20M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-110783 |
| us-gaap | WeightedAverageNumberDilutedSharesOutstandingAdjustment | Weighted Average Number Diluted Shares Outstanding Adjustment | shares | 53.22M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-10 | 0001564590-22-037385 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 154.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 30.81M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-12 | 0001564590-22-019895 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 154.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453674 |